J&J: Patients Treated With Nipocalimab Plus Soc Achieved Superiority Over Placebo Plus Soc as Measured by Primary Endpoint
J&J:使用Nipocalimab加Soc治療的患者在主要終點指標上比使用安慰劑加Soc更優秀
J&J: Patients Treated With Nipocalimab Plus Soc Achieved Superiority Over Placebo Plus Soc as Measured by Primary Endpoint
J&J:使用Nipocalimab加Soc治療的患者在主要終點指標上比使用安慰劑加Soc更優秀
譯文內容由第三人軟體翻譯。